Astria Therapeutics, Inc. (ATXS)
After hours:
| Previous close | 9.43 |
| Open | 9.51 |
| Bid | 9.53 x 200 |
| Ask | 9.57 x 300 |
| Day's range | 9.30 - 9.57 |
| 52-week range | 4.26 - 16.90 |
| Volume | |
| Avg. volume | 1,007,930 |
| Market cap | 523.871M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
BOSTON, May 09, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
- Business Wire
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
BOSTON, May 08, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present information on the preclinical profile of STAR-0310 at the upcoming Society for Investigative Dermatology (SID) Annual Meeting in Dallas, Texas on May 16, 2024.
- Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 02, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria’s common stock on May 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
